Last reviewed · How we verify
Vasopressin V2 Receptor Antagonist — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Vasopressin V2 Receptor Antagonist (Vasopressin V2 Receptor Antagonist) — Sanofi.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vasopressin V2 Receptor Antagonist TARGET | Vasopressin V2 Receptor Antagonist | Sanofi | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vasopressin V2 Receptor Antagonist CI watch — RSS
- Vasopressin V2 Receptor Antagonist CI watch — Atom
- Vasopressin V2 Receptor Antagonist CI watch — JSON
- Vasopressin V2 Receptor Antagonist alone — RSS
Cite this brief
Drug Landscape (2026). Vasopressin V2 Receptor Antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/vasopressin-v2-receptor-antagonist. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab